Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.21Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -8.68%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements, including strong new customer acquisition and improvements in cost management. However, these positives were offset by challenges in the BioPharma sector, a decline in Latin America, and overall flat revenue growth. The company is optimistic about future growth, particularly in the U.S. and with new applications like MSK-ACCESS and MSK-IMPACT.Company Guidance
During the SOPHiA GENETICS Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided guidance for 2025, projecting full-year revenue between $72 million and $76 million, representing a growth rate of 10% to 17%. This growth is primarily expected to be volume-driven, as the company anticipates a flat ASP for the year. The guidance reflects strong momentum from a record 92 new core genomic customers signed in 2024, with a focus on expediting implementation and expanding usage within these accounts. In 2024, SOPHiA GENETICS achieved a revenue of $65.2 million, within the guidance range, with an adjusted gross margin of 72.8%, up by 60 basis points, and an adjusted operating loss improved by 20% year-over-year. The company also highlighted its record analysis volume of 352,000 patients in 2024 and the expansion of its global reach to nearly 800 healthcare institutions across more than 70 countries. Looking forward, SOPHiA GENETICS aims to leverage its three key growth drivers: accelerating customer implementations, capitalizing on U.S. market momentum, and expanding groundbreaking applications like MSK-ACCESS and MSK-IMPACT.Record Number of New Customers
SOPHiA GENETICS signed 92 new core genomic customers in 2024, including 31 in Q4, a record for the company.
Improvement in Adjusted Operating Loss
The company improved its adjusted operating loss by 20% year-over-year and achieved a 60 basis point increase in adjusted gross margin.
Strong U.S. Market Performance
Clinical revenue in the U.S. grew by 23% in 2024, with analysis volume increasing by 26%.
MSK-ACCESS and MSK-IMPACT Applications Launch
The company launched MSK-ACCESS and MSK-IMPACT applications, with MSK-ACCESS being adopted by 34 customers across 20 countries.
Expansion into Japanese Market
SOPHiA GENETICS expanded into the Japanese market, collaborating with Genesis Healthcare to accelerate genomic testing access.
---
SOPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SOPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $3.57 | $3.10 | -13.17% |
| Nov 05, 2024 | $3.75 | $3.75 | 0.00% |
| Aug 06, 2024 | $4.15 | $4.06 | -2.17% |
| May 07, 2024 | $5.05 | $4.97 | -1.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SOPHiA GENETICS (SOPH) report earnings?
SOPHiA GENETICS (SOPH) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is SOPHiA GENETICS (SOPH) earnings time?
SOPHiA GENETICS (SOPH) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SOPH EPS forecast?
SOPH EPS forecast for the fiscal quarter 2025 (Q1) is -0.22.
---